Navigation Links
New York Genome Center announces the New York Stem Cell Foundation as an Associate Member
Date:9/17/2013

New York, NY (September 17, 2013) The New York Genome Center (NYGC) announced today that The New York Stem Cell Foundation (NYSCF) has become an Associate Member, joining NYGC's growing consortium of 16 research and clinical institutions, all working together in new ways to utilize genomic data for better detection, treatment, and prevention of disease.

"Biologists at the NYSCF working with the genomic scientists at NYGC will help address some of the critical roadblocks in stem cell research," said Dr. Robert B. Darnell, President and Scientific Director of NYGC. "Modern genomics has the potential to provide vital missing information to help us learn how to harness stem cells for use in clinical medicine. We've developed techniques and ideas here at NYGC that will greatly synergize with the beautiful and pioneering work ongoing at the NYSCF."

Stem cell biology and genomic analysis are both critical to the advancement of precision medicine. The collaboration between the Genome Center and NYSCF will merge cutting-edge capabilities in human biology with genomic research, creating an optimal environment for translating research into a better standard of care for patients.

"We are excited to work with NYGC as we continue to accelerate cures for the major diseases of our time. This will enable collaboration within the growing biotechnology community in New York," said Susan L. Solomon, CEO of The New York Stem Cell Foundation. "NYSCF has a number of current projects in which additional genomic analysis may play a critical role in better understanding disease susceptibility and risk factors. We hope to work with NYGC to integrate their genomic analysis into our research."

The New York Genome Center provides an "Integrated Genomics Solution", which includes (1) scientific consultation, (2) next-generation sequencing services for exomes, whole genomes, and RNA, (3) bioinformatic analysis of sequencing results using a high performance computing environment, and (4) data storage so that researchers and clinicians can readily access these results.

As an Associate Member, NYSCF will have priority access to these services. NYSCF will also become a member of the NYGC's Scientific and Clinical Steering Committee (SCSC), which provides guidance on research direction and oversees research collaborations and related funding.

NYSCF employs 45 full-time scientists and engineers in its laboratory who are engaged in the most advanced stem cell research and technology development, including creating NYSCF's Global Stem Cell Array, an automated technology platform that for the first time makes it possible to create identical stem cell lines from a large number of patients in a massively parallel process. This is a revolutionary tool that takes the vast amount of information we have learned from sequencing the human genome and puts it into a biological context to accelerate the development of safe and effective medicine. This robotic system creates induced pluripotent stem (iPS) cell lines and cell derivatives in a standardized manner from genetically diverse patients and patients with disease. This program will create an array of stem cell lines representing the full range of human genetics and the diversity of the world's population.

"This collaboration will expand our resources to analyze our stem cell samples at the genetic level, as we continue to bring the latest discoveries in genome science to our work to understand, prevent, and eventually cure diseases like diabetes, Alzheimer's, and multiple sclerosis among many others," said Scott Noggle, Director of the NYSCF Laboratory and the Charles Evans Senior Research Fellow for Alzheimer's Disease.

Human variability is what makes finding disease mechanisms and cures so difficult; however, leveraging NYGC's expertise and services to understand the genetic variability and gene expression of stem cell lines will help address why some people are affected by a disease and others are not. The promise of stem cell technology lies in creating human disease models in a dish. Therefore, combining genetic analysis with human iPS cell models creates a powerful tool for discovery.


'/>"/>

Contact: David McKeon
dmckeon@nyscf.org
212-365-7440
New York Stem Cell Foundation
Source:Eurekalert

Related biology news :

1. BGI and START initiate collaboration to advance unique San Antonio 1000 Cancer Genome Project
2. First study to investigate the human genome in multiple sclerosis
3. Unprecedented control of genome editing in flies promises insight into human development, disease
4. Tuberculosis genomes portray secrets of pathogens success
5. Whole-genome sequencing uncovers the mysteries of the endangered Chinese alligator
6. Full genome map of oil palm indicates a way to raise yields and protect rainforest
7. NIH funds new grants exploring use of genome sequencing in patient care
8. Genome assembly in the spotlight
9. First child born following embryo screening with new genome analysis technique
10. Genomes of cholera bacteria from Haiti confirm epidemic originated from single source
11. Genomes for science, genomes for life, and genomes for you and me
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2017)... -- Wake Forest Baptist Medical Center today announced Julie Ann Freischlag, ... (CEO). Freischlag joins the medical center on May 1 ... who last year announced that he would transition to ... it since 2008.   As CEO, Freischlag ... academic health system, which includes Wake Forest School of ...
(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2017  United ... announced its financial results for the fourth quarter ... annual 2016 financial results reflect continued growth as ... $700 million," said Martine Rothblatt, Ph.D., United Therapeutics, ... strengthen our ability to develop and advance our ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... Biopsy System , a fully automated benchtop system for collecting intact circulating tumor ... being launched at the Molecular Medicine Tri Conference (Tri-Con) Annual Meeting 2017 (February ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... -Sciences division, Treximo will pair its $200M operational capacity with its strategic ... project management in areas affecting quality and operational management. With office ...
(Date:2/21/2017)... Feb. 21, 2017  Lexus, a returning partner of the ... official and exclusive automobile partner of the men,s and women,s events ... The 2017 Amgen Tour of California ... some of the best professional cycling teams in the world racing ... The four-day Amgen Breakaway from Heart Disease TM ...
Breaking Biology Technology: